Optimizerx Corp (OptimizeRx) 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2011. OptimizeRx Corporation is a technology solutions company targeting the healthcare industry, transitioning from a development stage to an operating company. Its primary product, SampleMD, connects patients, physicians, and pharmaceutical manufacturers to facilitate the distribution of sample trial vouchers and co-pay coupons. The company is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Total Revenue | $393,843 | $1,283 |
| Net Loss | $(214,932) | $(260,967) |
| Operating Expenses | $469,281 | $263,094 |
| Cash and Cash Equivalents | $1,148,923 | $371,412 |
| Working Capital | $1,131,824 | N/A |
| Long-Term Debt | $1,000,000 | N/A |
| Net Cash Used in Operating Activities | $(91,561) | $(240,322) |
Debt and Liquidity: The company holds a $1,000,000 secured promissory note issued in October 2010, accruing interest at 6% per annum. As of March 31, 2011, total current liabilities were $874,593, and total assets were $3,553,459.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased significantly from $1,283 in Q1 2010 to $393,843 in Q1 2011, driven by the launch of the SampleMD solution and setup fees from pharmaceutical manufacturers.
- Expense Increase: Operating expenses rose by approximately 78% to $469,281, attributed to ramping up operations, increased professional fees ($106,214 vs. $16,603), and higher salaries ($173,714 vs. $137,224).
- Interest Expense: Other expenses increased to $140,000 due to the amortization of debt discount ($125,000) and interest on the new $1,000,000 note, compared to negligible interest in the prior year.
- Cash Flow Improvement: While the company remains cash-negative from operations, the cash burn rate improved significantly, with net cash used in operating activities decreasing from $240,322 to $91,561.
Outlook, Risks, and Contingencies
Management Commentary: Management believes the company has sufficient cash to operate for the next twelve months at current levels. However, achieving business goals depends on realizing cash revenues, meeting milestones for a second tranche of financing with Vicis Capital, or securing additional debt/equity financing.
Risks and Contingencies:
- Going Concern: The company has sustained substantial losses since inception. Continued operations depend on raising additional capital and revenue growth.
- Legal Proceedings:
- Sued Beringea, LLC for $400,000 regarding a capital raising agreement dispute (filed Feb 2011).
- Sued Midtown Partners & Co., LLC regarding a placement agent agreement dispute (filed Aug 2010, removed to federal court).
- Customer Concentration: Two major customers accounted for approximately 76% of revenues for the three months ended March 31, 2011.
- Debt Covenants: The $1,000,000 note includes restrictive covenants prohibiting dividends, share repurchases, and certain indebtedness until the note is paid.
Investor Verification Checklist
- Verify the status and potential outcome of the pending litigation against Beringea, LLC and Midtown Partners & Co.
- Confirm the company's ability to meet the milestones required to secure the second tranche of funding from Vicis Capital.
- Assess the sustainability of revenue given the high concentration (76%) from two major customers.
- Review the terms of the $1,000,000 secured promissory note, specifically the maturity date (Sept 2012) and the impact of the 6% interest rate plus amortization of debt discount on future cash flows.
- Monitor the company's cash burn rate relative to its current cash balance of ~$1.15 million to ensure the 12-month runway projection remains valid.